肾炎四味片联合阿魏酸哌嗪治疗慢性肾小球肾炎的临床研究
|
摘要
目的探讨肾炎四味片联合阿魏酸哌嗪治疗慢性肾小球肾炎患者的安全性与有效性。方法选取2015年4月—2017年4月于郑州市第一人民医院治疗的慢性肾小球肾炎患者136例,随机分成对照组(67例)和治疗组(69例)。对照组患者口服阿魏酸哌嗪片,3片/次,3次/d,治疗组患者在对照组基础上口服肾炎四味片,8片/次,3次/d;两组患者均连续治疗1月。观察两组患者临床疗效,同时比较治疗前后两组患者血清炎症因子和肾功能指标水平。结果治疗后,对照组和治疗组临床有效率分别为80.60%和95.65%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平均显著降低(P<0.05),而血清IL-2水平显著升高(P<0.05),且治疗组IL-6、TNF-α和IL-2水平明显优于对照组(P<0.05)。治疗后,两组患者24 h尿蛋白、血清胱抑素C、血肌酐水平均显著降低(P<0.05),且治疗组这些肾功能指标水平明显低于对照组(P<0.05)。结论肾炎四味片联合阿魏酸哌嗪治疗慢性肾小球肾炎临床有效率高,可减轻患者体内炎症水平,恢复肾功能的损伤,具有一定的临床推广应用价值。
Objective To investigate the safety and efficacy of Shenyan Siwei Tablets combined with piperazine ferulate in treatment of chronic glomerulonephritis. Methods Patients(136 cases) with chronic glomerulonephritis in the Medical Group of Zhengzhou First People's Hospital from April 2015 to April 2017 were randomly divided into control(67 cases) and treatment(69 cases) groups.Patients in the control group were po administered with Piperazine Ferulate Tablets, 3 tablets/time, three times daily. Patients in the treatment group were po administered with Shenyan Siwei Tablets on the basis of the control group, 8 tablets/time, three times daily.Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the serum inflammatory factors levels, the renal function markers levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 80.60% and 95.65% respectively, and there were differences between two groups(P < 0.05). After treatment, the serum IL-6 and TNF-α levels in two groups were significantly decreased(P < 0.05), but serum IL-2 levels were significantly increased(P < 0.05), and the IL-6, TNF-α and IL-2 levels in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the 24 h urinary protein, serum cystatin C and creatinine levels in two groups were significantly decreased(P < 0.05), and these renal function markers in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Shenyan Siwei Tablets combined with piperazine ferulate has significant effect in treatment of chronic glomerulonephritis, can reduce the level of inflammation and restore the renal function, which has a certain clinical application value.
Objective To investigate the safety and efficacy of Shenyan Siwei Tablets combined with piperazine ferulate in treatment of chronic glomerulonephritis. Methods Patients(136 cases) with chronic glomerulonephritis in the Medical Group of Zhengzhou First People's Hospital from April 2015 to April 2017 were randomly divided into control(67 cases) and treatment(69 cases) groups.Patients in the control group were po administered with Piperazine Ferulate Tablets, 3 tablets/time, three times daily. Patients in the treatment group were po administered with Shenyan Siwei Tablets on the basis of the control group, 8 tablets/time, three times daily.Patients in two groups were treated for 1 month. After treatment, the clinical efficacy was evaluated, and the serum inflammatory factors levels, the renal function markers levels in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups was 80.60% and 95.65% respectively, and there were differences between two groups(P < 0.05). After treatment, the serum IL-6 and TNF-α levels in two groups were significantly decreased(P < 0.05), but serum IL-2 levels were significantly increased(P < 0.05), and the IL-6, TNF-α and IL-2 levels in the treatment group were significantly better than those in the control group(P < 0.05). After treatment, the 24 h urinary protein, serum cystatin C and creatinine levels in two groups were significantly decreased(P < 0.05), and these renal function markers in the treatment group were significantly lower than those in the control group(P < 0.05). Conclusion Shenyan Siwei Tablets combined with piperazine ferulate has significant effect in treatment of chronic glomerulonephritis, can reduce the level of inflammation and restore the renal function, which has a certain clinical application value.
引文
[1]陈灏珠,钟南山,陆再英.内科学[M].第8版.北京:人民卫生出版社, 2013:473-475.
[2]杨倩春,杨霓芝.急性肾小球肾炎病因病机探讨[J].辽宁中医药大学学报, 2003, 5(1):13.
[3]刘桂范,李晓晗,于小娇.探讨阿魏酸哌嗪在慢性肾小球肾炎中的应用[J].中国伤残医学, 2013, 12(5):197.
[4]迟雁青,李英,冯珍,等.肾炎四味片对糖尿病大鼠肾脏保护作用的实验研究[J].河北医科大学学报,2010, 31(3):268-271, 306.
[5]中华中医药学会.慢性肾小球肾炎诊疗指南[J].中国中医药现代远程教育, 2011, 9(9):128-129.
[6]叶任高,陈裕盛,方敬爱.肾脏病诊断与治疗及疗效标准专题讨论纪要[J].中国中西医结合肾病杂志,2003,4(6):355-357.
[7]刘变玲,曹钋,阳白秀,等.慢性肾小球肾炎常见症状及证候要素的现代文献分析[J].中医学报,2012,27(9):1227-1229.
[8]王付民.慢性肾小球肾炎病理类型与中医分型相关性研究[J].辽宁中医杂志, 1994, 21(9):391-392.
[9]宣建宗,王亿平,丁仁华,等.中医及中西医结合治疗慢性肾小球肾炎研究进展[J].实用中医药杂志,2011,27(11):796-797.
[10]巫桁锞,李荣亨.阿魏酸及其衍生物在肾脏病中的应用[J].中国中西医结合肾病杂志, 2007, 8(12):740-743.
[11]杨红武,闵江莉,吴佳,等.肾炎四味颗粒药理作用的实验研究[J].中国药师, 2007, 10(1):20-24.
[12]张成禄,王前,谢健敏,等.慢性肾小球肾炎患者血清胱抑素C水平的变化及其诊断价值[J].实验与检验医学, 2010, 28(3):233-234, 242.
[13]常志远,徐荻.白细胞介素-2的研究进展[J].中国处方药, 2004, 12(8):36-38.
[14]谢建平,冯江超,张国元,等.慢性肾炎与相关细胞因子变化的研究[J].放射免疫学杂志,2003,16(6):348-350.
[2]杨倩春,杨霓芝.急性肾小球肾炎病因病机探讨[J].辽宁中医药大学学报, 2003, 5(1):13.
[3]刘桂范,李晓晗,于小娇.探讨阿魏酸哌嗪在慢性肾小球肾炎中的应用[J].中国伤残医学, 2013, 12(5):197.
[4]迟雁青,李英,冯珍,等.肾炎四味片对糖尿病大鼠肾脏保护作用的实验研究[J].河北医科大学学报,2010, 31(3):268-271, 306.
[5]中华中医药学会.慢性肾小球肾炎诊疗指南[J].中国中医药现代远程教育, 2011, 9(9):128-129.
[6]叶任高,陈裕盛,方敬爱.肾脏病诊断与治疗及疗效标准专题讨论纪要[J].中国中西医结合肾病杂志,2003,4(6):355-357.
[7]刘变玲,曹钋,阳白秀,等.慢性肾小球肾炎常见症状及证候要素的现代文献分析[J].中医学报,2012,27(9):1227-1229.
[8]王付民.慢性肾小球肾炎病理类型与中医分型相关性研究[J].辽宁中医杂志, 1994, 21(9):391-392.
[9]宣建宗,王亿平,丁仁华,等.中医及中西医结合治疗慢性肾小球肾炎研究进展[J].实用中医药杂志,2011,27(11):796-797.
[10]巫桁锞,李荣亨.阿魏酸及其衍生物在肾脏病中的应用[J].中国中西医结合肾病杂志, 2007, 8(12):740-743.
[11]杨红武,闵江莉,吴佳,等.肾炎四味颗粒药理作用的实验研究[J].中国药师, 2007, 10(1):20-24.
[12]张成禄,王前,谢健敏,等.慢性肾小球肾炎患者血清胱抑素C水平的变化及其诊断价值[J].实验与检验医学, 2010, 28(3):233-234, 242.
[13]常志远,徐荻.白细胞介素-2的研究进展[J].中国处方药, 2004, 12(8):36-38.
[14]谢建平,冯江超,张国元,等.慢性肾炎与相关细胞因子变化的研究[J].放射免疫学杂志,2003,16(6):348-350.